A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.

被引：0
|
作者：
Shapira, Roni
Weber, Jeffrey S.
Geva, Ravit
Sznol, Mario
Kluger, Harriet M.
Wong, Deborah J. L.
Liang, Bertrand C.
机构：
[1] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[2] NYU Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[4] Yale New Haven Med Ctr, Yale Sch Med, 20 York St, New Haven, CT 06504 USA
[5] Yale New Haven Med Ctr, Smilow Canc Ctr, 20 York St, New Haven, CT 06504 USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Kitov Pharma, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3094
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
    von Mehren, Margaret
    Britten, Carolyn D.
    Pieslor, Peter
    Saville, Wayne
    Vassos, Artemios
    Harris, Sarah
    Galluppi, Gerald R.
    Darif, Mohamed
    Wainberg, Zev A.
    Cohen, Roger B.
    Leong, Stephen
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 518 - 525
  • [42] A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
    Margaret von Mehren
    Carolyn D. Britten
    Peter Pieslor
    Wayne Saville
    Artemios Vassos
    Sarah Harris
    Gerald R. Galluppi
    Mohamed Darif
    Zev A. Wainberg
    Roger B. Cohen
    Stephen Leong
    Investigational New Drugs, 2014, 32 : 518 - 525
  • [43] Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia
    Huetter, Marie-Luise
    Fiedler, Walter
    Kuendgen, Andrea
    Krauter, Juergen
    von Lilienfeld-Toal, Marie
    Kayser, Sabine
    Rafler, Heidi
    Doehner, Hartmut
    Schlenk, Richard F.
    BLOOD, 2010, 116 (21) : 1350 - 1351
  • [44] Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open-Label, Single-Dose, Parallel-Group Study
    Bhardwaj, Rajinder
    Ivans, Andrea
    Stringfellow, Joseph
    Morris, Beth
    Coric, Vladimir
    Croop, Robert
    Bertz, Richard
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (08): : 790 - 800
  • [45] Rimegepant 75 mg in Subjects with Hepatic Impairment: Results of a Phase 1, Open-label, Single-dose, Parallel-group Study
    Croop, R.
    Stringfellow, J.
    Ivans, A.
    Coric, V
    HEADACHE, 2019, 59 : 178 - 178
  • [46] Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment
    Ivans, Andrea
    Stringfellow, Joseph
    Coric, Vladimir
    Croop, Robert
    NEUROLOGY, 2020, 94 (15)
  • [47] Results of a Phase 1, Open-label, Single-dose, Parallel-group Study of Rimegepant 75 mg in Subjects with Hepatic Impairment
    Croop, Robert
    Stringfellow, Joseph
    Ivans, Andrea
    Coric, Vladimir
    CEPHALALGIA, 2019, 39 : 200 - 200
  • [48] A dose escalation, open-label, phase I/II study of AME-527, a novel anti-TNF monoclonal antibody (mAb) in subjects with active rheumatoid arthritis (RA)
    Tutuncu, ZN
    Boyle, D
    Lee, S
    Hallinan, J
    Weber, J
    Vasserot, A
    Breitmeyer, J
    Kavanaugh, A
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S346 - S346
  • [49] Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies
    Ghobrial, Irene M.
    Savona, Michael R.
    Vij, Ravi
    Siegel, David S.
    Badros, Ashraf
    Kaufman, Jonathan L.
    Raje, Noopur
    Jakubowiak, Andrzej
    Obreja, Mihaela
    Berdeja, Jesus G.
    BLOOD, 2016, 128 (22)
  • [50] PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies
    Diab, A.
    Hurwitz, M. E.
    Tannir, N.
    Bernatchez, C.
    Haymaker, C.
    Bentebibel, S. E.
    Curti, B. D.
    Wong, M. K. K.
    Gergel, I.
    Tagliaferri, M.
    Zalevsky, J.
    Hoch, U.
    Aung, S.
    Imperiale, M.
    Cho, D.
    Tykodi, S. S.
    Puzanov, I.
    Kluger, H.
    Hwu, P.
    Sznol, M.
    ANNALS OF ONCOLOGY, 2017, 28
12345